Skip to main content
. 2024 Jul 18;16(16):1633–1648. doi: 10.1080/17568919.2024.2366147

Figure 6.

Figure 6.

2D presentation of pyridopyrimidine 5 with EGFR and CDK6 binding site versus Erlotinib and ligand PD0332991, respectively as references. (A) Binding of pyridopyrimidine 5 with EGFR, compared to Erlotinib binding, (B) Binding of pyridopyrimidine 5 with CDK6 versus the ligand PD0332991 binding.